Table of Contents
Overview
New York, NY – July 31, 2025 – The Point of Care Lipid Test Market Size is expected to be worth around US$ 1,449.4 million by 2034 from US$ 794.2 million in 2024, growing at a CAGR of 6.2% during the forecast period 2025 to 2034.
The global Point of Care (POC) Lipid Test market is witnessing substantial growth, driven by the rising prevalence of cardiovascular diseases, increasing demand for real-time diagnostics, and expanding access to decentralized healthcare services. These tests enable immediate lipid profiling total cholesterol, HDL, LDL, and triglycerides at the site of patient care, supporting timely clinical decision-making and enhanced disease management.
In 2024, the market showed steady expansion across hospitals, clinics, pharmacies, and home care settings. North America continues to dominate due to its advanced diagnostic infrastructure and rising preventive health awareness, while Asia Pacific is emerging as a high-growth region fueled by increased investments in primary care and health screening programs.
Technological advancements, such as biosensor-based devices and integrated digital connectivity, are enhancing the accuracy and usability of POC lipid tests. Additionally, government initiatives targeting early detection of cardiovascular risk factors and lifestyle-related diseases are expected to accelerate adoption globally.
The market is segmented by test type (panel and single test), end-user (hospitals, home care, diagnostic labs), and technology (immunoassay, biosensors). As the global healthcare system shifts towards preventive care and chronic disease management, point of care lipid testing is poised to play a pivotal role in improving cardiovascular health outcomes.
Key Takeaways
- In 2024, the global Point of Care Lipid Test market was valued at USD 794.2 million, and it is projected to reach USD 1,449.4 million by 2034, expanding at a compound annual growth rate (CAGR) of 6.2% over the forecast period.
- By product type, the market is segmented into Devices and Consumables. Among these, Consumables emerged as the leading segment in 2023, accounting for a market share of 62.2%, driven by frequent test usage and repeat purchases in clinical settings.
- In terms of application, the market is categorized into Hyperlipidemia, Hypertriglyceridemia, Tangier Disease, Hyperlipoproteinemia, Familial Hypercholesterolemia, and Others. Hyperlipidemia was the dominant application area, contributing 49.5% to the total market share, supported by the high global prevalence of lipid abnormalities.
- Based on indication, the market includes Lipid and Lipoprotein Disorders, Atherosclerosis, Liver and Renal Diseases, Diabetes Mellitus, and Others. Lipid and Lipoprotein Disorders represented the largest segment, capturing a 51.8% share in 2023.
- With regard to end-user, the market is segmented into Diagnostic Laboratories, Hospitals and Clinics, and Others. Diagnostic Laboratories held the largest revenue share of 49.8%, owing to their widespread role in routine lipid screening.
- Regionally, North America led the global market, securing a 42.8% market share in 2023, attributed to advanced healthcare infrastructure and rising preventive health measures.
Segmentation Analysis
- Product Type Analysis: The Consumables segment led the Point of Care Lipid Test Market with a 62.2% share in 2023, driven by high demand for test strips, cassettes, and cartridges. These components are used frequently with PoC devices, ensuring recurring revenue for manufacturers. Consumables are cost-effective and widely adopted in rural and decentralized settings. Their affordability, combined with the rising incidence of cardiovascular and lifestyle diseases, supports ongoing demand, especially as care shifts toward non-traditional healthcare environments.
- Application Analysis: Hyperlipidemia emerged as the dominant application, accounting for 49.5% of the market. It is a major risk factor for cardiovascular events and is increasingly common due to poor dietary habits, obesity, and physical inactivity. PoC lipid tests provide a rapid, accessible solution for monitoring cholesterol levels, enabling early detection and management. According to NCBI (2023), hyperlipidemia is present in up to 85% of premature CAD patients, underscoring the growing need for regular, convenient lipid screening.
- Indication Analysis: Lipid and Lipoprotein Disorders accounted for the largest share at 51.8%, reflecting the widespread burden of cholesterol, triglyceride, and lipoprotein imbalances. These conditions are key contributors to cardiovascular complications, particularly in aging and urban populations. Prevalence rates reach 25–30% in urban and 15–20% in rural settings. PoC lipid tests offer immediate diagnostic feedback, enabling timely intervention and linking directly to management of associated chronic illnesses such as diabetes and atherosclerosis.
- End-User Analysis: Diagnostic Laboratories held a leading 49.8% market share in 2024, due to their infrastructure and testing capacity. Equipped with skilled personnel and advanced technology, these facilities ensure accurate lipid profiling at scale. PoC devices integrated into diagnostic workflows allow for faster reporting, supporting prompt clinical decisions. High testing volumes also lower per-test costs, increasing affordability. These labs serve as primary centers for cardiovascular screening, playing a vital role in early risk assessment and disease prevention strategies.
Market Segments
By Product Type
- Devices
- Consumables
By Application
- Hyperlipidemia
- Hypertriglyceridemia
- Tangier Disease
- Hyperlipoproteinemia
- Familial Hypercholesterolemia
- Others
By Indication
- Lipid and Lipoprotein Disorders
- Atherosclerosis
- Liver and Renal Diseases
- Diabetes Mellitus
- Others
By End-User
- Diagnostic Laboratories
- Hospitals and Clinics
- Others
Regional Analysis
North America Leads the Point of Care Lipid Test Market
North America holds a leading position in the Point of Care (PoC) Lipid Test Market, driven by its advanced healthcare infrastructure, high cardiovascular disease (CVD) burden, and strong emphasis on preventive care. The region benefits from widespread adoption of PoC diagnostic technologies, supported by well-established healthcare systems and high awareness among both patients and providers.
The growing incidence of CVDs such as coronary artery disease and stroke has increased the demand for routine lipid monitoring. PoC lipid tests offer rapid, on-site results that facilitate timely clinical decisions, particularly in primary care, diagnostic labs, and home care settings. Rising healthcare expenditures have further reinforced the shift toward cost-effective and decentralized testing solutions.
The market is also supported by favorable regulatory frameworks from agencies such as the U.S. Food and Drug Administration (FDA) and continuous innovation from leading diagnostic manufacturers. Additionally, the expansion of telehealth and remote patient management continues to boost regional demand. Consequently, North America is expected to retain its market leadership in the forecast period.
Emerging Trends
- Inclusion of Lp(a) Measurement: Point-of-care (POC) lipid devices are beginning to incorporate assays for lipoprotein (a), a key cardiovascular risk marker. In mid-2025, the FDA cleared the Tina-quant® Lipoprotein (a) Gen.2 assay for POC use, enabling clinicians to assess hereditary risk factors at the bedside.
- Strengthened Standardization Efforts: The Centers for Disease Control and Prevention’s Cholesterol Reference Method Laboratory Network (CRMLN) has updated its certification protocols to ensure POC lipid tests meet stringent accuracy and precision criteria. This enhances confidence that POC results align with central laboratory values for total cholesterol, HDL-C, LDL-C, and triglycerides.
- Multi-Analyte Platforms: Modern POC systems are converging multiple tests into a single device. For example, the Cholestech LDX™ System now pairs a full lipid panel with blood glucose measurement, allowing five analytes total cholesterol, HDL, triglycerides, calculated LDL, non-HDL and glucose to be reported from a single fingerstick sample.
- Adoption in Epidemiological Research: Studies have demonstrated that POC lipid analyzers like the CardioChek® PA deliver reliable data for large-scale health surveys. Their portability and rapid results have supported field studies without the need for central lab infrastructure, facilitating real-time cardiovascular risk assessments in diverse populations.
Use Cases
- Community Health Screenings: Community clinics and health fairs can screen large groups quickly. POC devices process a fingerstick sample (≈40 µL) in just 5 minutes. From 2017–2020, an estimated 86.4 million US adults had high or borderline high cholesterol, underscoring the need for accessible screening outside traditional labs.
- Pediatric School Programs: Children aged 9–11 are recommended to have one cholesterol check. POC lipid testing in schools can use a tiny blood drop and deliver results in 5 minutes, making it feasible to test hundreds of students per session and identify the roughly 20% of adolescents with unhealthy cholesterol levels.
- Integrated Diabetes and Dyslipidemia Management: In outpatient diabetes clinics, the Cholestech LDX™ System enables simultaneous measurement of blood glucose plus a full lipid panel. With just 40 µL of blood, clinicians can obtain six analyte results supporting rapid therapy adjustments in under 5 minutes and improving coordination of glycemic and lipid control.
- Field Epidemiological Surveys: Researchers conducting population health studies rely on portable POC analyzers like the CardioChek® PA, which measures total cholesterol, triglycerides, HDL-C, and LDL-C on site. This capability streamlines data collection in remote or resource-limited settings, accelerating survey throughput and reducing sample transport delays.
Conclusion
The global Point of Care (PoC) Lipid Test market is positioned for sustained growth, supported by the rising prevalence of cardiovascular diseases, technological innovation, and the shift toward preventive and decentralized healthcare. The increasing adoption of biosensor-based and multi-analyte devices enhances diagnostic efficiency across hospitals, home care, and field settings.
With North America maintaining its leadership due to advanced infrastructure and Asia Pacific showing strong potential, the market is expected to expand at a CAGR of 6.2% through 2034. Growing use in community screenings, pediatric care, and epidemiological research further underscores its critical role in improving cardiovascular outcomes.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
